{"title":"High prevalent early damage independently predicts future mortality in an inception cohort of Takayasu arteritis.","authors":"Durga Prasanna Misra,Upendra Rathore,Tooba Qamar,Kritika Singh,Deeksha Singh,Ranjeet Singh Chauhan,Sara Abid,Rudrarpan Chatterjee,Able Lawrence,Amita Aggarwal,Manas Ranjan Behera,Roopali Khanna,Neeraj Jain,Manish Ora","doi":"10.1093/rheumatology/keaf508","DOIUrl":null,"url":null,"abstract":"OBJECTIVES\r\nTo evaluate early damage, its evolution, and prognostic relevance in an inception cohort of Takayasu arteritis (TAK) using the Large Vessel Vasculitis Index of Damage (LVVID).\r\n\r\nMETHODS\r\nLVVID was scored in an inception cohort of TAK within 3 months of cohort entry, at one year, and the last follow-up at or after one year. Association between initial LVVID scores and demographic characteristics, disease activity, and angiographic subtypes were evaluated. Hazard ratios (HR) for mortality per point/quartile increase in baseline LVVID scores were calculated using Cox proportional hazards regression. Damage evolution from baseline to one year or last follow-up was compared using paired Student's t test. Pre-treatment predictors of progression were assessed using logistic regression.\r\n\r\nRESULTS\r\nAmong 199 patients (141 females, pediatric-onset 54), 192/199 (96.5%) had damage (most often cardiovascular) scored on LVVID at presentation, 112/114 (98.2%) at one year, and 126/130 (96.9%) at last follow-up. Initial LVVID was greater with active disease, Hata's type V, or Goel's cluster 1 angiographic subtypes. Higher baseline LVVID was associated with increased mortality [crude HR per point increase 1.49 (95%CI 1.24-1.80) or per quartile increase in LVVID 1.92 (1.21-3.05)] consistent despite adjustment for disease activity or angiographic subtype. Significant progression of LVVID was observed at 1 year (3.49 ± 2.01 vs 3.27 ± 1.86, p< 0.001) or at the last follow-up (3.73 ± 2.18 vs 3.28 ± 1.88 p< 0.001), predicted by active disease at presentation (OR 2.89) and glucocorticoid (OR 3.53) or immunosuppressant use (OR 3.52).\r\n\r\nCONCLUSION\r\nMost patients with TAK had recordable early damage which predicted future mortality.","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":"319 1","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/rheumatology/keaf508","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
OBJECTIVES
To evaluate early damage, its evolution, and prognostic relevance in an inception cohort of Takayasu arteritis (TAK) using the Large Vessel Vasculitis Index of Damage (LVVID).
METHODS
LVVID was scored in an inception cohort of TAK within 3 months of cohort entry, at one year, and the last follow-up at or after one year. Association between initial LVVID scores and demographic characteristics, disease activity, and angiographic subtypes were evaluated. Hazard ratios (HR) for mortality per point/quartile increase in baseline LVVID scores were calculated using Cox proportional hazards regression. Damage evolution from baseline to one year or last follow-up was compared using paired Student's t test. Pre-treatment predictors of progression were assessed using logistic regression.
RESULTS
Among 199 patients (141 females, pediatric-onset 54), 192/199 (96.5%) had damage (most often cardiovascular) scored on LVVID at presentation, 112/114 (98.2%) at one year, and 126/130 (96.9%) at last follow-up. Initial LVVID was greater with active disease, Hata's type V, or Goel's cluster 1 angiographic subtypes. Higher baseline LVVID was associated with increased mortality [crude HR per point increase 1.49 (95%CI 1.24-1.80) or per quartile increase in LVVID 1.92 (1.21-3.05)] consistent despite adjustment for disease activity or angiographic subtype. Significant progression of LVVID was observed at 1 year (3.49 ± 2.01 vs 3.27 ± 1.86, p< 0.001) or at the last follow-up (3.73 ± 2.18 vs 3.28 ± 1.88 p< 0.001), predicted by active disease at presentation (OR 2.89) and glucocorticoid (OR 3.53) or immunosuppressant use (OR 3.52).
CONCLUSION
Most patients with TAK had recordable early damage which predicted future mortality.
期刊介绍:
Rheumatology strives to support research and discovery by publishing the highest quality original scientific papers with a focus on basic, clinical and translational research. The journal’s subject areas cover a wide range of paediatric and adult rheumatological conditions from an international perspective. It is an official journal of the British Society for Rheumatology, published by Oxford University Press.
Rheumatology publishes original articles, reviews, editorials, guidelines, concise reports, meta-analyses, original case reports, clinical vignettes, letters and matters arising from published material. The journal takes pride in serving the global rheumatology community, with a focus on high societal impact in the form of podcasts, videos and extended social media presence, and utilizing metrics such as Altmetric. Keep up to date by following the journal on Twitter @RheumJnl.